Budesonide Dosing and Safety Considerations

Respiratory Conditions

The American Academy of Allergy, Asthma, and Immunology recommends budesonide dosing for asthma management, varying significantly by age and disease severity, ranging from 88-176 mcg daily for low-dose therapy in children to >352 mcg daily for high-dose therapy in adults when delivered via metered-dose inhaler 1
For children under 4 years, budesonide nebulizer suspension is recommended at 0.25-0.5 mg for low dose, up to 1.0 mg for medium dose 1
For adults with asthma, 176 mcg (low dose) to >352 mcg (high dose) via HFA/MDI is recommended 1

The American Gastroenterological Association recommends budesonide 9 mg once daily for 8 weeks as the first-line therapy for microscopic colitis or ileocecal Crohn's disease 2, 3
After achieving remission, tapering over 1-2 weeks is recommended rather than abrupt discontinuation 3
Budesonide should not be used for long-term maintenance therapy beyond 6-12 months due to adverse effects including adrenal suppression and bone loss 3

The National Institutes of Health recommends monitoring for adrenal suppression and bone health with prolonged use of budesonide 4
Local side effects include oral candidiasis, dysphonia, and throat irritation 1
CYP3A4 inhibitors (ritonavir, ketoconazole) can significantly increase systemic budesonide concentrations and risk of Cushing syndrome 1
Face washing after inhalation reduces local adverse effects 1